FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214891384> ?p ?o ?g. }

• W4214891384 abstract "Levodopa remains the most effective symptomatic treatment for Parkinson's disease (PD) more than 50 years after its clinical introduction. However, the onset of motor complications can limit pharmacological intervention with levodopa, which can be a challenge when treating PD patients. Clinical data suggest using the lowest possible levodopa dose to balance the risk/benefit. Istradefylline, an adenosine A2A receptor antagonist indicated as an adjunctive treatment to levodopa-containing preparations in PD patients experiencing wearing off, is currently available in Japan and the US. Preclinical and preliminary clinical data suggested that adjunctive istradefylline may provide sustained antiparkinsonian benefits without a levodopa dose increase; however, available data on the impact of istradefylline on levodopa dose titration are limited. The ISTRA ADJUST PD study will evaluate the effect of adjunctive istradefylline on levodopa dosage titration in PD patients.This 37-week, multicenter, randomized, open-label, parallel-group controlled study in PD patients aged 30-84 years who are experiencing the wearing-off phenomenon despite receiving levodopa-containing medications ≥ 3 times daily (daily dose 300-400 mg) began in February 2019 and will continue until February 2022. Enrollment is planned to attain 100 evaluable patients for the efficacy analyses. Patients will receive adjunctive istradefylline (20 mg/day, increasing to 40 mg/day) or the control in a 1:1 ratio, stratified by age, levodopa equivalent dose, and presence/absence of dyskinesia. During the study, the levodopa dose will be increased according to symptom severity. The primary study endpoint is the comparison of the cumulative additional dose of levodopa-containing medications during the treatment period between the adjunctive istradefylline and control groups. Secondary endpoints include changes in efficacy rating scales and safety outcomes.This study aims to clarify whether adjunctive istradefylline can reduce the cumulative additional dose of levodopa-containing medications in PD patients experiencing the wearing-off phenomenon, and lower the risk of levodopa-associated complications. It is anticipated that data from ISTRA ADJUST PD will help inform future clinical decision-making for patients with PD in the real-world setting.Japan Registry of Clinical Trials, jRCTs031180248 ; registered 12 March 2019." @default.
• W4214891384 created "2022-03-05" @default.
• W4214891384 creator A5000254886 @default.
• W4214891384 creator A5005942334 @default.
• W4214891384 creator A5009652158 @default.
• W4214891384 creator A5020403627 @default.
• W4214891384 creator A5022458683 @default.
• W4214891384 creator A5025441142 @default.
• W4214891384 creator A5028175156 @default.
• W4214891384 creator A5031367385 @default.
• W4214891384 creator A5032670400 @default.
• W4214891384 creator A5034233382 @default.
• W4214891384 creator A5036693411 @default.
• W4214891384 creator A5038472221 @default.
• W4214891384 creator A5039446593 @default.
• W4214891384 creator A5040694556 @default.
• W4214891384 creator A5043614995 @default.
• W4214891384 creator A5049747372 @default.
• W4214891384 creator A5054170148 @default.
• W4214891384 creator A5061148778 @default.
• W4214891384 creator A5062372349 @default.
• W4214891384 creator A5066742789 @default.
• W4214891384 creator A5067171570 @default.
• W4214891384 creator A5069360446 @default.
• W4214891384 creator A5071345881 @default.
• W4214891384 creator A5084716950 @default.
• W4214891384 creator A5087533507 @default.
• W4214891384 creator A5090620748 @default.
• W4214891384 date "2022-03-03" @default.
• W4214891384 modified "2023-10-10" @default.
• W4214891384 title "Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson’s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study" @default.
• W4214891384 cites W1493115321 @default.
• W4214891384 cites W1680009796 @default.
• W4214891384 cites W1778152931 @default.
• W4214891384 cites W1900332198 @default.
• W4214891384 cites W1990269363 @default.
• W4214891384 cites W2009775147 @default.
• W4214891384 cites W2010485061 @default.
• W4214891384 cites W2023819204 @default.
• W4214891384 cites W2026913930 @default.
• W4214891384 cites W2028129201 @default.
• W4214891384 cites W2038918555 @default.
• W4214891384 cites W2040227196 @default.
• W4214891384 cites W2070912312 @default.
• W4214891384 cites W2078208735 @default.
• W4214891384 cites W2088277236 @default.
• W4214891384 cites W2108369591 @default.
• W4214891384 cites W2108901766 @default.
• W4214891384 cites W2112455323 @default.
• W4214891384 cites W2115222037 @default.
• W4214891384 cites W2115639304 @default.
• W4214891384 cites W2121928725 @default.
• W4214891384 cites W2126008330 @default.
• W4214891384 cites W2142803792 @default.
• W4214891384 cites W2153020583 @default.
• W4214891384 cites W2169802060 @default.
• W4214891384 cites W2172651064 @default.
• W4214891384 cites W2193789687 @default.
• W4214891384 cites W2403629665 @default.
• W4214891384 cites W2615535085 @default.
• W4214891384 cites W2761736404 @default.
• W4214891384 cites W2775013655 @default.
• W4214891384 cites W2792396898 @default.
• W4214891384 cites W2895194501 @default.
• W4214891384 cites W2941828104 @default.
• W4214891384 cites W2944852150 @default.
• W4214891384 cites W2952895828 @default.
• W4214891384 cites W2969616509 @default.
• W4214891384 cites W3003486628 @default.
• W4214891384 cites W3006012411 @default.
• W4214891384 cites W3007448887 @default.
• W4214891384 cites W3008248930 @default.
• W4214891384 cites W3010983304 @default.
• W4214891384 cites W3011519974 @default.
• W4214891384 cites W3161511225 @default.
• W4214891384 cites W37005 @default.
• W4214891384 cites W4241279990 @default.
• W4214891384 doi "https://doi.org/10.1186/s12883-022-02600-w" @default.
• W4214891384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35241003" @default.
• W4214891384 hasPublicationYear "2022" @default.
• W4214891384 type Work @default.
• W4214891384 citedByCount "3" @default.
• W4214891384 countsByYear W42148913842022 @default.
• W4214891384 countsByYear W42148913842023 @default.
• W4214891384 crossrefType "journal-article" @default.
• W4214891384 hasAuthorship W4214891384A5000254886 @default.
• W4214891384 hasAuthorship W4214891384A5005942334 @default.
• W4214891384 hasAuthorship W4214891384A5009652158 @default.
• W4214891384 hasAuthorship W4214891384A5020403627 @default.
• W4214891384 hasAuthorship W4214891384A5022458683 @default.
• W4214891384 hasAuthorship W4214891384A5025441142 @default.
• W4214891384 hasAuthorship W4214891384A5028175156 @default.
• W4214891384 hasAuthorship W4214891384A5031367385 @default.
• W4214891384 hasAuthorship W4214891384A5032670400 @default.
• W4214891384 hasAuthorship W4214891384A5034233382 @default.
• W4214891384 hasAuthorship W4214891384A5036693411 @default.
• W4214891384 hasAuthorship W4214891384A5038472221 @default.
• W4214891384 hasAuthorship W4214891384A5039446593 @default.
• W4214891384 hasAuthorship W4214891384A5040694556 @default.
• W4214891384 hasAuthorship W4214891384A5043614995 @default.

• next